Verrica Q1 2025: YCANTH revenue $3.4M; dispensed 10,102 units (+16.7% QoQ)

Verrica Pharmaceuticals Inc.

2025-Q1 EPS reported -$0.10 revenue$3,439,000

Net loss $9.7M ($0.10/share) vs. $20.3M ($0.44) in Q1 2024; non-GAAP net loss $7.8M.
YCANTH revenue $3.4M from >10K applicator units dispensed, a company record and 16.7% sequential growth.
Cash and equivalents $29.6M as of March 31, 2025.
Appointed Noah Rosenberg as CMO (March) and Gavin Corcoran to Board (April).
Completed end-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); global Phase 3 for common warts advancing with Torii.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.